ARCT
Arcturus Therapeutics Holdings, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website arcturusrx.com
- Employees(FY) 170
- ISIN nan
Performance
-0.05%
1W
-14.54%
1M
-3.22%
3M
-32.72%
6M
-41.83%
YTD
+3.56%
1Y
Profile
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Technical Analysis of ARCT 2024-11-13
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-11 17:19
- 2024-11-11 16:01
- 2024-11-11 03:01
- 2024-11-09 09:25
- 2024-11-08 12:15
Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-07 16:01
- 2024-11-07 13:29
- 2024-11-07 04:55
- 2024-11-07 03:48
Arcturus Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
- 2024-11-07 03:01
- 2024-11-06 07:35
- 2024-11-04 10:05
- 2024-10-31 16:01
- 2024-10-31 04:01
- 2024-10-30 12:00
- 2024-10-24 07:23
- 2024-10-23 04:00
A slow start for self-amplifying mRNA vaccines(Pharmaceutical Technology)
- 2024-10-01 10:46
- 2024-09-30 11:12
- 2024-09-30 08:00
- 2024-09-29 20:00
- 2024-09-16 11:28
- 2024-09-13 08:48
- 2024-09-13 08:15
- 2024-09-13 07:13
- 2024-09-12 20:15
- 2024-09-12 10:07
Top High Growth Tech Stocks to Watch in September 2024(Simply Wall St.)
- 2024-09-08 16:51
- 2024-09-08 04:51
- 2024-09-07 23:49
10 Worst ARK Stocks To Buy According To Short Sellers(Insidermonkey)
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.